Literature DB >> 7532080

Cyclo-oxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy.

A Tomlinson1, I Appleton, A R Moore, D W Gilroy, D Willis, J A Mitchell, D A Willoughby.   

Abstract

1. The profiles of cyclo-oxygenase (COX) and nitric oxide synthase (NOS) isoforms were determined in the rat carrageenin-induced pleurisy model of acute inflammation. 2. The enzymes were assessed in peripheral blood leucocyte (PBL) cell pellets taken from untreated animals and at 2, 6 and 24 h after injection of the irritant in pleural exudate cell pellets and lung homogenates. 3. COX activity was assessed by the generation of prostacyclin (PGI2, measured as the stable metabolite, 6-keto prostaglandin F1 alpha) and prostaglandin E2 (PGE2). Western blot analysis and immunohistochemistry were also carried out. 4. NOS activity was based on the conversion of [3H]-L-arginine to [3H]-L-citrulline in the presence (total NOS activity) or absence of Ca2+ (inducible NOS; iNOS). 5. Peripheral blood leucocyte samples contained low levels of COX activity. In pleural exudate cell pellets, COX activity peaked at 2 to 6 h after injection of the carrageenin. At 24 h, COX activity was significantly reduced. 6. Western blot analysis demonstrated that the inducible isoform of COX (COX-2), was the predominant enzyme at all time points. Low levels of COX-2 were seen in PBLs. In pleural exudate cell pellets maximal COX-2 protein levels were seen at 2 h. 7. Immunohistochemistry confirmed the findings of Western blot studies. Approximately 10% of polymorphonuclear neutrophils (PMNs) in PBLs from untreated animals were immunopositive for COX-2. In cell pellet smears from carrageenin-induced pleurisy taken 2 h after injection of the irritant, PMNs were also the major source of COX-2 immunoreactivity. A small proportion of macrophages and mesothelial cells were also immunolabelled for COX-2.8. Low levels of NOS activity were seen in PBLs. In pleural exudates NOS activity was maximum at 6 h and greatly reduced by 24 h. This activity was solely attributable to iNOS.9. The present results illustrated a similar profile of COX and NOS activity in the carrageenin-induced pleurisy model of acute inflammation. It was demonstrated that COX-2 and iNOS were the predominant isoforms of their respective enzymes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7532080      PMCID: PMC1510410          DOI: 10.1111/j.1476-5381.1994.tb17048.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  Macrophage synthesis of nitrite, nitrate, and N-nitrosamines: precursors and role of the respiratory burst.

Authors:  R Iyengar; D J Stuehr; M A Marletta
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

2.  Altered arachidonic acid metabolism during differentiation of the human monoblastoid cell line U937.

Authors:  L Koehler; R Hass; K Wessel; D L DeWitt; V Kaever; K Resch; M Goppelt-Struebe
Journal:  Biochim Biophys Acta       Date:  1990-02-23

3.  Acetylcholine and bradykinin relax intrapulmonary arteries by acting on endothelial cells: role in lung vascular diseases.

Authors:  N Chand; B M Altura
Journal:  Science       Date:  1981-09-18       Impact factor: 47.728

4.  Characterization of the L-arginine:nitric oxide pathway in human platelets.

Authors:  M W Radomski; R M Palmer; S Moncada
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

5.  Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion.

Authors:  T B McCall; N K Boughton-Smith; R M Palmer; B J Whittle; S Moncada
Journal:  Biochem J       Date:  1989-07-01       Impact factor: 3.857

6.  Generation of nitric oxide by human neutrophils.

Authors:  C D Wright; A Mülsch; R Busse; H Osswald
Journal:  Biochem Biophys Res Commun       Date:  1989-04-28       Impact factor: 3.575

7.  Role of endothelial cells in relaxation of isolated arteries by bradykinin.

Authors:  P D Cherry; R F Furchgott; J V Zawadzki; D Jothianandan
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

8.  Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate.

Authors:  M A Marletta; P S Yoon; R Iyengar; C D Leaf; J S Wishnok
Journal:  Biochemistry       Date:  1988-11-29       Impact factor: 3.162

9.  Prostacyclin biosynthesis in cultured vascular endothelium is limited by deactivation of cyclooxygenase.

Authors:  A F Brotherton; J C Hoak
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

10.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.

Authors:  R M Palmer; A G Ferrige; S Moncada
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

View more
  44 in total

1.  A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.

Authors:  L C Hamilton; I Vojnovic; T D Warner
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Calpain inhibitor I reduces the development of acute and chronic inflammation.

Authors:  S Cuzzocrea; M C McDonald; E Mazzon; D Siriwardena; I Serraino; L Dugo; D Britti; G Mazzullo; A P Caputi; C Thiemermann
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  The tyrosine kinase inhibitor tyrphostin AG126 reduces the development of acute and chronic inflammation.

Authors:  S Cuzzocrea; M C McDonald; E Mazzon; D Siriwardena; G Calabrò; D Britti; G Mazzullo; A De Sarro; A P Caputi; C Thiemermann
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

Review 4.  Aspirin and other anti-inflammatory drugs.

Authors:  S J Vane
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

5.  Professor Derek Albert Willoughby (1930-2004).

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

6.  Expression of COX-1 and COX-2 in a clinical model of acute inflammation.

Authors:  Asma A Khan; Michael Iadarola; Hsiu-Ying T Yang; Raymond A Dionne
Journal:  J Pain       Date:  2007-01-30       Impact factor: 5.820

Review 7.  Novel pharmacological strategies for analgesia.

Authors:  M Perkins; A Dray
Journal:  Ann Rheum Dis       Date:  1996-10       Impact factor: 19.103

8.  Inhibitory effect of anethole in nonimmune acute inflammation.

Authors:  Talita Perdigão Domiciano; Márcia Machado de Oliveira Dalalio; Expedito Leite Silva; Alessandra Mileni Versuti Ritter; Camila Fernanda Estevão-Silva; Fernando Seara Ramos; Silvana Martins Caparroz-Assef; Roberto Kenji Nakamura Cuman; Ciomar Aparecida Bersani-Amado
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-19       Impact factor: 3.000

9.  Reduced infiltration and increased apoptosis of leukocytes at sites of inflammation by systemic administration of a membrane-permeable IkappaBalpha repressor.

Authors:  Nathan M Blackwell; Phupinder Sembi; Justine S Newson; Toby Lawrence; Derek W Gilroy; Panagiotis S Kabouridis
Journal:  Arthritis Rheum       Date:  2004-08

10.  The effects of cyclooxygenase 2 inhibitors on cartilage erosion and bone loss in a model of Mycobacterium tuberculosis-induced monoarticular arthritis in the rat.

Authors:  D W Gilroy; A Tomlinson; K Greenslade; M P Seed; D A Willoughby
Journal:  Inflammation       Date:  1998-10       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.